MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS

BEYSEL, Selvihan; Kizilgul, Muhammed; Çilekar, Murat; ÇALIŞKAN, Muhammed Mustafa Tuncer; ÖZBEK, Mustafa Cem; ÖZÇELİK, Özgür; ÇAKAL, Erman

MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS

Selvihan BEYSEL, (Afyonkarahisar Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, Endokrinoloji ve Metabolizma Bilim Dalı, Afyonkarahisar, Türkiye)

Muhammed Mustafa Tuncer ÇALIŞKAN, (Atatürk Düzce Devlet Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Düzce, Türkiye)

Muhammed KIZILGÜL, (Dışkapı Yıldırım Beyazıt Eğitim Araştırma Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Özgür ÖZÇELİK, (Ankara Şehir Hastanesi, Endokronoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Murat ÇİLEKAR, (Afyonkarahisar Sağlık Bilimleri Üniversitesi, Tıp Fakültesi, Genel Cerrahi Anabilim Dalı, Afyonkarahisar, Türkiye)

Mustafa Cem ÖZBEK, (Dışkapı Yıldırım Beyazıt Eğitim Araştırma Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Erman ÇAKAL (Dışkapı Yıldırım Beyazıt Eğitim Araştırma Hastanesi, Endokrinoloji ve Metabolizma Kliniği, Ankara, Türkiye)

Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi

2 0

Yıl: 2019 Cilt: 20 Sayı: özel sayı Sayfa Aralığı: 201 - 207 Metin Dili: İngilizce İndeks Tarihi: 24-11-2020

MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS

Öz:

OBJECTIVE: The monocyte count to HDL-Cholesterol ratio(MHR) was increased in patients with cardiovascular disease and,showed as an indicator of cardiovascular risk factors. Functionaladrenal tumor and even nonfunctional adrenal adenomas areassociated with an increased risk for cardiovascular disease.This is the first study to evaluate the MHR value in patients withadrenal tumors, and examine its relation with cardiometabolicrisk factors.MATERIAL AND METHODS: Twenty-four patients with functional adrenal tumor (10 Cushing syndrome, 12 pheochromocytoma, and 2 primary hyperaldosteronism), patients with non-functional adrenal adenoma (n=33) and,control subjects (n=50) were included. Anthropometric,hormonal and biochemical results, lipid panel, fastingplasma glucose (FPG), blood pressure (BP), blood cellcounts, high-sensitivity C-reactive protein (hs-CRP), andcarotid intima-media thickness (CIMT) were compared.RESULTS: Mean age (51.14±2.03 vs 54.01±9.37 years), sexdistribution (female 66.7 % vs 73.8 %), and body mass index(31.12±3.38 vs 30.46±2.96 kg/m2) were similar betweenadrenal tumor and control group (respectively, p>0.05).The MHR value was higher in the functional tumor groupcompared with the non-functional adenoma and control group(13.79±3.14, 10.19±2.84 vs 10.08±1.82, respectively, p<0.05).MHR value was similar between the non-functional adenomaand controls (p>0.05). MHR value was positively correlated withsystolic BP (r=0.480, p<0.001), diastolic BP (r=0.452, p<0.001),FPG (r=0.333, p=0.001), hs-CRP (r=0.538, p=0.001) and,urinary normetanephrine concentrations (r=0.302, p=0.043).Functional adrenal tumor with cardiovascular disease hadhigher MHR value compared with those without cardiovasculardisease (14.69±2.67 vs 11.84±2.57, p<0.05).CONCLUSIONS: The MHR value was increased in patientswith functional adrenal tumor; however it did not increasein patients with nonfunctional adenoma. MHR value wascorrelated with cardio-metabolic risk factors such as FPG, BP,and hs-CRP. The MHR value suggests as a predictive marker forcardiometabolic risk factors in functional adrenal tumors.

Anahtar Kelime:

MONOSİT SAYISININ HDL-KOLESTEROLE ORANI FONKSİYONEL ADRENAL TÜMÖRLÜ HASTALARDA YENİ BİR KARDİYOMETABOLİK BELİRTEÇ OLABİLİR

Öz:

AMAÇ: Monosit sayısının HDL-Kolesterole oranı (MHO), kardiyovasküler hastalığı olan hastalarda yüksek bulunmuş ve kardiyovasküler risk faktörleri için belirteç olduğu gösterilmiş. Fonksiyonel adrenal tümör ve fonksiyonel olmayan adrenal adenomlu hastalarda bile kardiyovasküler hastalık riski artmaktadır. Bu çalışmada ilk olarak, MHO’nun adrenal tümörlü hastalarda yüksek olup olmadığı ve kardiyometabolik risk faktörleri ile ilişkisi araştırıldı. GEREÇ VE YÖNTEM: Çalışmaya fonksiyonel adrenal tümürü olan 24 hasta (10 Cushing sendromu, 12 feokromositoma ve 2 primer hiperaldosteronizm), fonksiyonel olmayan adrenal adenomlu hasta (n=33) ve kontrol olgusu (n=50) alındı. Antropometrik inceleme, hormon ve biyokimyasal sonuçlar, lipid paneli, açlık kan şekeri (AKŞ), kan basıncı (KB), tam kan sayımı, C-reaktif protein (hs-CRP) ve karotis intima-media kalınlığı (KIMK) karşılaştırıldı. BULGULAR: Ortalama yaş (51.14±2.03’e karşın 54.01±9.37 yıl), cinsiyet dağılımı (kadın 66.7 %’a karşın 73.8 %) ve vücut kitle indeksi (31.12±3.38’a karşın 30.46±2.96 kg/m2) adrenal tümör ve kontrol grubu arasında benzerdi (sırasıyla, p>0.05). MHO değeri fonksiyonel tümör grubunda, fonksiyonel olmayan adenom ve kontrol grubuna göre, yüksek bulundu (13.79±3.14, 10,19±2,84 vs 10.08±1.82, sırasıyla, p<0.05). MHO değeri fonksiyonel olmayan adenom ve kontrol grubu arasında benzer bulundu (p>0,05). MHO değeri sistolik KB (r=0.480; p<0.001), diyastolik KB (r=0.452; p<0.001), AKŞ (r=0.333; p=0.001), hs-CRP (r=0.538, p=0.001) ve idrar normetanefrin düzeyi (r=0.302; p=0.043) ile pozitif korele idi. Kardiyovasküler hastalığı olan fonksiyonel adrenal tümörlü hastalarda, kardiyovasküler hastalığı olmayan fonksiyonel adrenal tümörlü hastalara göre, MHR değeri yüksek bulundu (14.69±2.67’e karşın 11.84±2.57, p<0.05). SONUÇ: Monosit sayısının HDL-Kolesterole oranı fonksiyonel adrenal tümörlü hastalarda yüksek bulunurken; fonksiyonel olmayan adenomlu hastalarda yüksek değildi. Monosit sayısının HDL-Kolesterole oranı kardiyometabolik risk faktörleri olan AKŞ, KB ve hs-CRP ile korele idi. Monosit sayısının HDL-Kolesterole oranı, fonksiyonel adrenal tümörlü hastalarda kardiyovasküler risk faktörleri için prediktif belirteç olabilir.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ganjali S, Gotto AM, Ruscica M et al. Monocyte-to-HDLcholesterol ratio as a prognostic marker in cardiovascular diseases. J. Cell. Physiol. 2018;233(12):9237–46.
2. Kızılgül M, Calışkan M, Uçan B et al. Monocyte to HDL Cholesterol Ratio and its association with cardiometabolic risk factors in Primary Hyperparathyroidism. Medeniyet Medical Journal 2018;33(2):94-9.
3. Canpolat U, Çetin EH, Cetin S. Association of Monocyteto-HDL Cholesterol Ratio with Slow Coronary Flow is linked to Systemic Inammation. Clin. Appl. Thromb. O. J. Int. Acad. Clin. Appl. Thromb. 2016; 22(5):476–82.
4. Açıkgöz S, Açıkgöz E, Şensoy B et al. Monocyte to highdensity lipoprotein cholesterol ratio is predictive of inhospital and five-year mortality in ST-segment elevation myocardial infarction. Cardiol. J. 2016; 23(5):505–12.
5. Ammirati E, Moroni F, Magnoni M et al. Circulating CD14+ and CD14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. Atherosclerosis 2016;255(1):171–8.
6. Bolayir A, Gokce SF, Cigdem B et al. Monocyte/highdensity lipoprotein ratio predicts the mortality in ischemic stroke patients. Neurol. Neurochir. Pol. 2018;52(2):150–5.
7. Gratchev A, Sobenin I, Orekhov A et al. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiology 2012;217(5):476–82.
8. You S, Zhong C, Zheng D et al. Monocyte to HDL cholesterol ratio is associated with discharge and 3-month outcome in patients with acute intracerebral hemorrhage. J. Neurol. Sci. 2017;372:157–61.
9. Kundi H, Gok M, Kiziltunc E et al. Relation between Monocyte to High-Density Lipoprotein Cholesterol Ratio with Presence and Severity of Isolated Coronary Artery Ectasia. Am. J. Cardiol. 2015;116(11):1685–89.
10. Cetin MS, Ozcan Cetin EH, Kalender E et al. Monocyte to HDL Cholesterol Ratio Predicts Coronary Artery Disease Severity and Future Major Cardiovascular Adverse Events in Acute Coronary Syndrome. Heart Lung Circ. 2016;25(11):1077–86.
11. Zhang Y, Li S, Guo Y-L et al. Is monocyte to HDL ratio superior to monocyte count in predicting the cardiovascular outcomes: evidence from a large cohort of Chinese patients undergoing coronary angiography. Ann. Med. 2016;48(5):305–12.
12. Lopez D, Luque-Fernandez MA, Steele A et al. “Nonfunctional” Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study. Ann. Intern. Med. 2016;165(8):533–42.
13. Yener S, Cömlekci A, Yuksel F et al. Traditional and novel cardiovascular risk factors in non-functioning adrenal adenomas. Eur. J. Intern. Med. 2012;23(1):83–7.
14. Di Dalmazi G, Vicennati V, Garelli S et al. Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing’s syndrome: a 15-year retrospective study. Lancet Diabetes Endocrinol. 2014;2(5):396–405.
15. Gu YW, Poste J, Kunal M et al. Cardiovascular Manifestations of Pheochromocytoma. Cardiol. Rev. 2017;25(5):215–22.
16. Prejbisz A, Warchoł-Celińska E, Lenders JWM et al. Cardiovascular Risk in Primary Hyperaldosteronism. Horm. Metab. Res. Horm. Stowechselforschung Horm. Metab. 2015;47(13):973–80.
17. Morelli V, Reimondo G, Giordano R et al. Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. J. Clin. Endocrinol. Metab. 2014;99(3):827–34.
18. Aron D, Terzolo M, Cawood TJ. Adrenal incidentalomas. Best Pract. Res. Clin. Endocrinol. Metab. 2012;26(1):69–82.
19. Kizilgul M, Beysel S, Ozcelik O et al. PENTRAXIN 3 AS A NEW CARDIOVASCULAR MARKER IN ADRENAL ADENOMAS. Endocr. Pract. O. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 2017;23(6):662–8.
20. Petrák O, Rosa J, Holaj R et al. Blood Pressure Profile, Catecholamine Phenotype and Target Organ Damage in Pheochromocytoma/Paraganglioma. J. Clin. Endocrinol. Metab.2019-02644.
21. Park J, De Luca A, Dutton H et al. Cardiovascular Outcomes in Autonomous Cortisol Secretion and Nonfunctioning Adrenal Adenoma: A Systematic Review. J. Endocr. Soc. 2019;3(5):996–1008.
22. Savard S, Amar L, Plouin P-F et al. Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertens. Dallas Tex 1979 2013;62(2):331–6.
23. Zelinka T, Petrák O, Turková H et al. High incidence of cardiovascular complications in pheochromocytoma. Horm. Metab. Res. Horm. Stowechselforschung Horm. Metab. 2012;44(5):379–84.
24. Boero L, Manavela M, Botta E et al. CONDITIONING FACTORS FOR HIGH CARDIOVASCULAR RISK IN PATIENTS WITH CUSHING SYNDROME. Endocr. Pract. O. J. Am. Coll. Endocrinol. Am. Assoc. Clin. Endocrinol. 2015;21(7):734– 42.
25. Scaroni C, Zilio M, Foti M et al. Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. Endocr. Rev. 2017;38(3):189– 219.
26. Widimský J. Primary hyperaldosteronism: common cause of secondary hypertension with higher cardiovascular risk. Vnitr. Lek. 2013;59(6):501–4.
27. Abad-Cardiel M, Alvarez-Álvarez B, Luque-Fernandez L et al. Hypertension caused by primary hyperaldosteronism: increased heart damage and cardiovascular risk. Rev. Espanola Cardiol. Engl. Ed 2013;66(1):47–52.
28. Wu C, Zhang H, Zhang J et al. Inammation and Fibrosis in Perirenal Adipose Tissue of Patients with Aldosterone-Producing Adenoma. Endocrinology 2018;159(1):227–37.
29. Zelinka T, Petrák O, Strauch B et al. Elevated inammation markers in pheochromocytoma compared to other forms of hypertension. Neuroimmunomodulation 2007;14(1):57–64.
30. Papanastasiou L, Alexandraki KI, Androulakis II et al. Concomitant alterations of metabolic parameters, cardiovascular risk factors and altered cortisol secretion in patients with adrenal incidentalomas during prolonged follow-up. Clin. Endocrinol. (Oxf.) 2017;86(4):488–98.
31. Tuna MM, Imga NN, Doğan BA et al. Nonfunctioning adrenal incidentalomas are associated with higher hypertension prevalence and higher risk of atherosclerosis. J. Endocrinol. Invest. 2014;37(8):765–8.
32. Imga NN, Elalmıs OU, Tuna MM et al. Comparison of echocardiographic findings in patients with nonfunctioning adrenal incidentalomas. Kaohsiung J. Med. Sci. 2017;33(6):295–301.
33. Evran M, Akkuş G, Berk Bozdoğan İ et al. Carotid Intima-Media Thickness as the Cardiometabolic Risk Indicator in Patients with Nonfunctional Adrenal Mass and Metabolic Syndrome Screening. Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2016;22:991–7.
34. Yener S, Baris M, Secil M et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction? J. Endocrinol. Invest. 2011;34(4):265– 70.
35. Androulakis II, Kaltsas GA, Kollias GE et al. Patients with apparently nonfunctioning adrenal incidentalomas may be at increased cardiovascular risk due to excessive cortisol secretion. J. Clin. Endocrinol. Metab. 2014;99(8):2754–62.
36. Akkus G, Evran M, Sert M et al. Adipocytokines in Nonfunctional Adrenal Incidentalomas and Relation with Insulin Resistance Parameters. Endocr. Metab. Immune Disord. Drug Targets 2019;19(3):326–32.
37. Wei X-B, Chen F, Huang J-L et al. Novel Risk Biomarker for Infective Endocarditis Patients With Normal Left Ventricular Ejection Fraction- Monocyte to High-Density Lipoprotein Cholesterol Ratio. Circ. J. O. J. Jpn. Circ. Soc. 2017;82(1):283–8.
38. Akboga MK, Balci KG, Maden O et al. Usefulness of monocyte to HDL-cholesterol ratio to predict high SYNTAX score in patients with stable coronary artery disease. Biomark. Med. 2016;10(4):375–83.
39. Yayla KG, Canpolat U, Yayla Ç et al. A Novel Marker of Impaired Aortic Elasticity in Never Treated Hypertensive Patients: Monocyte/High-Density Lipoprotein Cholesterol Ratio. Acta Cardiol. Sin. 2017; 33(1):41–9.
40. Aydin E, Ates I, Fettah Arikan et al. The ratio of monocyte frequency to HDL cholesterol level as a predictor of asymptomatic organ damage in patients with primary hypertension. Hypertens. Res. O. J. Jpn. Soc. Hypertens. 2017;40(8):758–64.
41. Çiçek G, Kundi H, Bozbay M et al. The relationship between admission monocyte HDL-C ratio with shortterm and long-term mortality among STEMI patients treated with successful primary PCI. Coron. Artery Dis. 2016;27(3):176–84.
42. Inonu Koseoglu H, Pazarli AC, Kanbay A et al. Monocyte Count/HDL Cholesterol Ratio and Cardiovascular Disease in Patients With Obstructive Sleep Apnea Syndrome: A Multicenter Study. Clin. Appl. Thromb. O. J. Int. Acad. Clin. Appl. Thromb. 2018;24(1):139–44.
43. Kanbay M, Solak Y, Unal HU et al. Monocyte count/ HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. Int. Urol. Nephrol. 2014;46(8):1619–25.
44. Vahit D, Akboga MK, Samet Y et al. Assessment of monocyte to high density lipoprotein cholesterol ratio and lymphocyte-to-monocyte ratio in patients with metabolic syndrome. Biomark. Med. 2017;11(7):535–40.

APA	BEYSEL S, ÇALIŞKAN M, Kizilgul M, ÖZÇELİK Ö, Çilekar M, ÖZBEK M, ÇAKAL E (2019). MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. , 201 - 207.
Chicago	BEYSEL Selvihan,ÇALIŞKAN Muhammed Mustafa Tuncer,Kizilgul Muhammed,ÖZÇELİK Özgür,Çilekar Murat,ÖZBEK Mustafa Cem,ÇAKAL Erman MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. (2019): 201 - 207.
MLA	BEYSEL Selvihan,ÇALIŞKAN Muhammed Mustafa Tuncer,Kizilgul Muhammed,ÖZÇELİK Özgür,Çilekar Murat,ÖZBEK Mustafa Cem,ÇAKAL Erman MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. , 2019, ss.201 - 207.
AMA	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. . 2019; 201 - 207.
Vancouver	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. . 2019; 201 - 207.
IEEE	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E "MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS." , ss.201 - 207, 2019.
ISNAD	BEYSEL, Selvihan vd. "MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS". (2019), 201-207.

APA	BEYSEL S, ÇALIŞKAN M, Kizilgul M, ÖZÇELİK Ö, Çilekar M, ÖZBEK M, ÇAKAL E (2019). MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 20(özel sayı), 201 - 207.
Chicago	BEYSEL Selvihan,ÇALIŞKAN Muhammed Mustafa Tuncer,Kizilgul Muhammed,ÖZÇELİK Özgür,Çilekar Murat,ÖZBEK Mustafa Cem,ÇAKAL Erman MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 20, no.özel sayı (2019): 201 - 207.
MLA	BEYSEL Selvihan,ÇALIŞKAN Muhammed Mustafa Tuncer,Kizilgul Muhammed,ÖZÇELİK Özgür,Çilekar Murat,ÖZBEK Mustafa Cem,ÇAKAL Erman MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, vol.20, no.özel sayı, 2019, ss.201 - 207.
AMA	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2019; 20(özel sayı): 201 - 207.
Vancouver	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2019; 20(özel sayı): 201 - 207.
IEEE	BEYSEL S,ÇALIŞKAN M,Kizilgul M,ÖZÇELİK Ö,Çilekar M,ÖZBEK M,ÇAKAL E "MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS." Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 20, ss.201 - 207, 2019.
ISNAD	BEYSEL, Selvihan vd. "MONOCYTE COUNT TO HDL-CHOLESTEROL RATIO MAY BE A NOVEL CARDIOMETABOLIC MARKER IN PATIENTS WITH FUNCTIONAL ADRENAL TUMORS". Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 20/özel sayı (2019), 201-207.